Licensing

Almirall has entered into a licensing agreement with Eloxx Pharmaceuticals Inc. to develop and commercialize ZKN-013 for the treatment of orphan dermatological diseases, according to an Almirall press release.

A United Kingdom-based biotech company has announced a global licensing agreement with a California pharma firm to research and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Arcutis Biotherapeutics and Hangzhou Zhongmei Huadong Pharmaceutical Co. have entered into a strategic collaboration and licensing agreement to develop and commercialize Zoryve in China and Southeast Asia, according to a press release.

Research has shown that questions about physicians’ mental health on state licensing and credentialing applications often discourage them from seeking mental health treatment.

Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites, according to a press release.

Conformis Inc. has entered into definitive agreements to sell and license certain assets relating to patient-specific instrumentation technology to Stryker Corporation, and to develop, manufacture and supply patient-specific instrumentation for use in connection with Stryker’s knee implant offerings.